Log in
NASDAQ:HOLX

Hologic Stock Forecast, Price & News

$64.35
+1.34 (+2.13 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$62.45
Now: $64.35
$64.44
50-Day Range
$57.60
MA: $63.64
$70.25
52-Week Range
$26.49
Now: $64.35
$73.63
Volume1.11 million shs
Average Volume2.64 million shs
Market Capitalization$16.67 billion
P/E Ratio26.05
Dividend YieldN/A
Beta1.4
Hologic, Inc., a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. The company offers Aptima molecular diagnostic assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and analytics products, such as 2D and 3D mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, and breast biopsy and biopsy site markers, as well as localization, specimen radiology, ultrasound, and connectivity solutions. In addition, the company offers Selenia Dimensions and 3Dimensions gantries for performing 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D software products; SecurView Workstations; computer aided detection systems; and stereotactic breast biopsy systems. Further, it provides SculpSure, PicoSure, and MonaLisa Touch aesthetic treatment systems; TempSure, a radio frequency energy sourced platform; and MedLite and other products, and system components for medical aesthetics. Additionally, the company offers NovaSure, an endometrial ablation system to treat women suffering from abnormal uterine bleeding; MyoSure surgical products for removal of fibroids, and uterine polyps and other pathology; and Horizon DXA System and Fluoroscan Insight FD skeletal health products. It sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. The company was founded in 1985 and is headquartered in Marlborough, Massachusetts.
Read More
Hologic logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.73 out of 5 stars


Industry, Sector and Symbol

Industry X-ray apparatus & tubes
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:HOLX
CUSIP43644010
Phone508-263-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.37 billion
Cash Flow$4.46 per share
Book Value$7.91 per share

Profitability

Net Income$-203,600,000.00

Miscellaneous

Employees6,478
Market Cap$16.67 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$64.35
+1.34 (+2.13 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HOLX News and Ratings via Email

Sign-up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Hologic (NASDAQ:HOLX) Frequently Asked Questions

How has Hologic's stock been impacted by COVID-19 (Coronavirus)?

Hologic's stock was trading at $43.78 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HOLX stock has increased by 47.0% and is now trading at $64.35.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Hologic?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Hologic
.

When is Hologic's next earnings date?

Hologic is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Hologic
.

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) posted its earnings results on Wednesday, July, 29th. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.37. The medical equipment provider had revenue of $822.90 million for the quarter, compared to analyst estimates of $622.96 million. Hologic had a net margin of 20.03% and a return on equity of 31.40%. The business's revenue was down 3.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.63 EPS.
View Hologic's earnings history
.

What guidance has Hologic issued on next quarter's earnings?

Hologic issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Friday, September, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.225-1.275 billion, compared to the consensus revenue estimate of $989 million.

What price target have analysts set for HOLX?

14 brokerages have issued 1 year target prices for Hologic's shares. Their forecasts range from $43.00 to $85.00. On average, they expect Hologic's stock price to reach $66.57 in the next twelve months. This suggests a possible upside of 3.5% from the stock's current price.
View analysts' price targets for Hologic
.

Are investors shorting Hologic?

Hologic saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 3,600,000 shares, an increase of 22.4% from the August 31st total of 2,940,000 shares. Based on an average daily volume of 2,390,000 shares, the days-to-cover ratio is presently 1.5 days. Approximately 1.4% of the shares of the stock are sold short.
View Hologic's Short Interest
.

Who are some of Hologic's key competitors?

What other stocks do shareholders of Hologic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hologic investors own include AbbVie (ABBV), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), Walt Disney (DIS), Abbott Laboratories (ABT), CVS Health (CVS), Pfizer (PFE), Paypal (PYPL) and Advanced Micro Devices (AMD).

Who are Hologic's key executives?

Hologic's management team includes the following people:
  • Mr. Stephen P. MacMillan, Chairman, CEO & Pres (Age 55)
  • Ms. Karleen M. Oberton, Chief Financial Officer (Age 49)
  • Mr. John M. Griffin, Gen. Counsel (Age 58)
  • Mr. Peter J. Valenti III, Division Pres of Breast & Skeletal Health Solutions (Age 56)
  • Mr. Thomas A. West, Division Pres of Diagnostics Solutions (Age 55)

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

Who are Hologic's major shareholders?

Hologic's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.15%), FMR LLC (3.29%), Nuveen Asset Management LLC (1.41%), Marshall Wace North America L.P. (1.02%), Bank of New York Mellon Corp (0.77%) and Two Sigma Advisers LP (0.73%). Company insiders that own Hologic stock include Allison P Bebo, Benjamin Jordan Cohn, Christiana Stamoulis, John M Griffin, Karleen Marie Oberton, Peter J Valenti III, Sally Crawford and Stephen P Macmillan.
View institutional ownership trends for Hologic
.

Which major investors are selling Hologic stock?

HOLX stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Prudential Financial Inc., Man Group plc, Goldman Sachs Group Inc., Charles Schwab Investment Management Inc., Bank of Montreal Can, AJO LP, and Wedge Capital Management L L P NC. Company insiders that have sold Hologic company stock in the last year include Benjamin Jordan Cohn, Christiana Stamoulis, John M Griffin, Karleen Marie Oberton, Peter J Valenti III, Sally Crawford, and Stephen P Macmillan.
View insider buying and selling activity for Hologic
.

Which major investors are buying Hologic stock?

HOLX stock was bought by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Deerfield Management Company L.P. Series C, Point72 Asset Management L.P., MUFG Securities EMEA plc, Avidity Partners Management LP, Frontier Capital Management Co. LLC, Teacher Retirement System of Texas, and Smith Asset Management Group LP.
View insider buying and selling activity for Hologic
.

How do I buy shares of Hologic?

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Hologic's stock price today?

One share of HOLX stock can currently be purchased for approximately $64.35.

How big of a company is Hologic?

Hologic has a market capitalization of $16.67 billion and generates $3.37 billion in revenue each year. The medical equipment provider earns $-203,600,000.00 in net income (profit) each year or $2.43 on an earnings per share basis. Hologic employs 6,478 workers across the globe.

What is Hologic's official website?

The official website for Hologic is www.hologic.com.

How can I contact Hologic?

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.